Made Scientific Announced Major Expansion of New Jersey Cell Therapy Manufacturing Hub

• Made Scientific is expanding its Princeton, New Jersey facility with an additional 9,000 sq. ft. of GMP manufacturing space across two phases, beginning in Q2 2025.

• The expansion aims to support late-stage and commercial cell therapy programs, increasing manufacturing throughput by up to 2,000 batches annually.

Made Scientific, a cell therapy contract development and manufacturing organisation (CDMO), has announced a substantial expansion of its Princeton, New Jersey facility to address growing demand from late-phase and commercial clients. The 12,000 sq. ft. project includes more than 9,000 sq. ft. of new GMP manufacturing cleanroom space to be delivered in two phases.

The first phase is set to begin in Q2 2025 and complete by Q3 2026, with Phase 2 to follow. The facility is designed to meet U.S. FDA and EU Annex 1 compliance standards and will feature high-throughput ballroom manufacturing, advanced bioprocessing systems, and expanded quality control (QC) infrastructure. Once complete, the site will enable up to 2,000 additional manufacturing batches annually.

“This expansion delivers exactly that—a purpose-built, globally compliant platform designed to scale programs efficiently, meet regulatory expectations, and help our partners bring life-changing therapies to market with confidence,” said Syed T. Husain, Chairman and CEO of Made Scientific.

The Princeton headquarters currently includes six ISO 7 / Grade B cleanrooms, development laboratories, and in-house QC testing. The new investment builds on existing digital infrastructure, including quality and manufacturing execution systems from Veeva, Autolomous, and Oracle NetSuite, supporting integrated program oversight.

Made Scientific’s broader offering includes early-phase manufacturing at its Newark site, as well as a workforce development programme combining hands-on and virtual training in cell therapy biomanufacturing. The expanded Princeton site is expected to play a central role in delivering contract manufacturing services for autologous and allogeneic therapies progressing toward commercialisation.